Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension
{{output}}
The development of parenteral prostacyclin therapy marked a dramatic breakthrough in the treatment of pulmonary arterial hypertension (PAH). Intravenous (IV) epoprostenol was the first PAH specific therapy and to date, remains the only treatment to demonstrate... ...
